In metabolic disorders like diabetes, melatonin demonstrates its antioxidant capabilities by normalizing malondialdehyde (MDA) and myeloperoxidase (MPO) levels while reducing cleaved caspase-3 expression, which signals its role in mitigating cellular damage (Abdulwahab et al., 2021). This evidence concerns the gene MPO and metabolic disease.